Eric Sunol

Dr. Eric Suñol is a co-founder and Managing Partner of Inveniam Group, a boutique advisory firm he launched in 2013 alongside co-founder Elena Canetti. He also serves as the firm's CEO. Inveniam positions itself at the intersection of "science, business and finance," helping innovators in health, sustainability, and deep tech navigate the path from research to commercial market through positioning, funding, and partnership development.

Under Suñol's leadership, Inveniam has grown into a multi-office practice — with a Barcelona headquarters and additional presence in Madrid and Tel Aviv — built around a team of Managing Partners including Elena Canetti, Dr. Albert Cot, and John Crockett. The firm describes its work as technology transfer, corporate finance, and strategy advisory focused on technology-based transactions in Life Sciences and Resource Sustainability, and in 2023 marked its 10-year anniversary.

Beyond pure advisory, Suñol and Inveniam sponsor an investment vehicle that channels a selected group of seasoned investors into early-stage life-sciences and sustainability technology companies — effectively giving Suñol an angel/seed-investor role in addition to his advisory work. He is listed on the firm's site as "Dr. Eric Suñol," indicating a doctoral background consistent with the firm's deep science-and-technology orientation.

• Invests at the seed / early stage in technology-based companies within Life Sciences, Sustainability, and Deep Tech.
• Works through an Inveniam-sponsored investment vehicle composed of "a selected group of seasoned investors that invest expecting very high returns," focused on early-stage life-sciences and sustainability technology companies.
• Typically acts as a co-investor rather than lead, connecting companies to Inveniam's established VC and business-angel networks specialized in life sciences, deep tech, and sustainability.
• Values companies that are (or can be made) "investor-ready" — Inveniam builds financial strategies and materials before making introductions, so a clear commercialization path and capital-readiness matter.
• Emphasizes bridging science, business, and finance, so scientifically credible, IP-backed innovations with a route from research to market fit the thesis.